Research output per year
Research output per year
Personal profile
Professional Information
I am medical oncologist trained in Chile and formally trained again at the National Cancer Institute National Institutes of Health, Bethesda MD, obtaining my second oncology fellowship. Additionally, I have received direct lung cancer training from prestigious investigators such as Guiseppe Giacconne MD and medical Oncology mentorship by Antonio Fojo.
Research Interests
My main interest are immuno-oncology specific diseases such as lung cancer, renal cancer and melanoma and areas in medicine like Health policy and biostatistics.
I was editor of the Seminar in Oncology journal and currently I am one of the editors of Journal of Thoracic Oncology.
I have participated in more than 50 publications in indexed journals and have written several medical oncology books chapters.
I am also the Medical Director of the Cancer Center of Clínica Universidad de los Andes and the Medical Director of Bradford Hill clinical research center and have participated as principal investigator in more than 30 cancer clinical trials.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Medical Director, Bradford Hill Clinical Research Center.
1 Mar 2019 → …
Fingerprint
Dive into the research topics where Mauricio Burotto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
McGregor, B., Geynisman, D. M., Burotto, M., Suárez, C., Bourlon, M. T., Barata, P. C., Gulati, S., Huo, S., Ejzykowicz, F., Blum, S. I., Del Tejo, V., Hamilton, M., May, J. R., Du, E. X., Wu, A., Kral, P., Ivanescu, C., Chin, A., Betts, K. A., Lee, C. H., & 3 others, 1 Jun 2023, In: European urology oncology. 6, 3, p. 339-348 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Yang, J. C. H., Liu, G., Lu, S., He, J., Burotto, M., Ahn, M. J., Kim, D. W., Liu, X. Q., Zhao, Y., Vincent, S., Yin, J., Ma, X., Lin, H. M. & Popat, S., 2023, (Accepted/In press) In: Journal of Thoracic Oncology.Research output: Contribution to journal › Article › peer-review
Open Access -
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
COSMIC-313 Investigators, 11 May 2023, In: New England Journal of Medicine. 388, 19, p. 1767-1778 12 p.Research output: Contribution to journal › Article › peer-review
9 Scopus citations -
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S. N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., Zanghi, J. A., Leutgeb, B. & Felip, E., Aug 2023, In: Annals of Oncology. 34, 8, p. 693-702 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
MAP4K4 and cancer: ready for the main stage?
González-Montero, J., Rojas, C. I. & Burotto, M., 2023, In: Frontiers in Oncology. 13, 1162835.Research output: Contribution to journal › Short survey › peer-review
Open Access
Press/Media
-
Findings from Brigham and Women's Hospital Update Knowledge of Carcinomas (Cabozantinib Plus Nivolumab and Ipilimumab In Renal-cell Carcinoma)
22/08/23
1 item of Media coverage
Press/Media
-
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
3/03/23
2 items of Media coverage
Press/Media
-
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
28/02/23
1 item of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma
27/02/23
1 item of Media coverage
Press/Media
-
Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma
23/02/23
2 items of Media coverage
Press/Media